1094346-39-0

Basic information

• Product Name: 1,4-dimethyl-1H-imidazole-5-carbohydrazide
• Synonyms: 1,4-dimethyl-1H-imidazole-5-carbohydrazide
• CAS NO: 1094346-39-0
• Molecular Formula: C₆H₁₀N₄O
• Molecular Weight: 154.1698
• Mol File: 1094346-39-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,4-dimethyl-1H-imidazole-5-carbohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dimethyl-1H-imidazole-5-carbohydrazide(1094346-39-0)
• EPA Substance Registry System: 1,4-dimethyl-1H-imidazole-5-carbohydrazide(1094346-39-0)

Safety Data

• Hazardous Substances Data: 1094346-39-0(Hazardous Substances Data)

Usage

Chemical structure

Imidazole derivative with 1,4-dimethyl substitution and a carbohydrazide functional group

Functional groups

1,4-dimethyl substitution, carbohydrazide functional group

Usage

Commonly used as a reagent in organic synthesis

Industries

Pharmaceutical and chemical industries

Applications

Building block for the synthesis of various compounds, potential applications in medicinal chemistry, intermediate in the production of materials such as polymers and resins.

Upstream product

• 35445-32-0 ethyl 1,4-dimethyl-1H-imidazole-5-carboxylate 
• 51605-32-4 ethyl 4⁽⁵⁾-methylimidazole-5⁽⁴⁾-carboxylate 

Downstream Products

• 1094342-63-8 3-chloro-5-[(6-chloro-3-{[5-(1,4-dimethyl-1H-imidazol-5-yl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 

Relevant articles and documents

Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human

The discovery and optimization of a novel series of GPR142 agonists are described. These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.